Screening for Diabetic Retinopathy Proven to be Cost-Effective in China

Both telemedicine and community screening for diabetic retinopathy (DR) in rural and urban settings are cost-effective in China, and telemedicine screening programs are more cost-effective, according to a study led by a group of ophthalmologists and economists.

The results were published in Health Data Science, a Science Partner Journal.

Diabetic retinopathy (DR) may affect 116 million people with diabetes mellitus (DM) in China, a country with an immense DM disease burden. Although regular screening and timely treatment are essential to prevent onset/progress of DR and reduce the economic burden from the vision-threatening complications, two-thirds of DM patients have not received frequent screening in China. Furthermore, with a higher prevalence of DR, patients' awareness of DR in rural areas is lower than in urban areas in China.

"Diabetic retinopathy (DR) has been primarily indicated to cause vision impairment and blindness," says Hanruo Liu, associate professor with Beijing Institute of Ophthalmology, Beijing Tongren Hospital. "However, no studies have focused on the cost-utility of telemedicine- based and community screening programs for DR in diabetes mellitus patients in China, especially in rural and urban areas, respectively."

"To fill the identified gaps, we developed a Markov model to calculate the cost-utility of screening programs for DR in diabetes mellitus patients in rural and urban settings from the societal perspective," says Liu. She explains how the study addressed the disparity of disease burden in the country. "Our study is the first to analyze the cost-utility of telemedicine compared with community screening programs for DR in diabetes mellitus patients under rural and urban settings in China using a Markov model, from the societal perspective."

The study reveals that both community and telemedicine screening are highly cost-effective in all areas, whether rural or urban. For example, in rural settings, one QALY (quality-adjusted life year) was gained through community and telemedicine screening at the cost of $4,179 and $2,323. Likewise, per QALY gained in rural areas, community screening took $3,812, and telemedicine screening cost $2,437.

"The results suggest that both telemedicine and community screening for DR in rural and urban settings were cost-effective. It is more economically reasonable to adopt telemedicine screening programs at the national primary care level," Liu says as she explains the key finding from the study.

When describing how screening interval affects cost and wellbeing, Liu says, "We also derived screening every two years by telemedicine in diabetes mellitus patients was the best type of screening and interval combination both in rural and urban settings."

Regardless of the strategies and settings in this analysis, the screening programs remained beneficial and cost-effective: within one per capita GDP. "In the existing studies, telemedicine screening programs for DR have been proven cost-effective, although most studies were conducted in high-income nations. Therefore, our results are more likely applicable under settings with low labor costs and a high prevalence of DR with low opportunistic detection rates, such as low-income and middle-income nations," says Liu.

"In the future, the use of validated automated grading software based on artificial intelligence (AI) will improve the cost-utility and cost-effectiveness of screening. Moreover, with the development of technology for telecommunication, cloud storage, miniaturization of equipment and application of AI to the automatic interpretation of retinal images, there may be further optimization in productivity, quality assurance, and sustainability." Liu shares her insight on how their study is relevant to the dearth of skilled retinal specialists and image graders.

"However, the cost-utility of these new technologies should be evaluated before clinical implementation." Liu leaves a cautious remark on the inspiring study. A larger landscape is on the horizon, as Liu says, "Ultimately, we aimed at developing a new screening pattern for common eye diseases combined with multiple ophthalmic examinations and the integration of AI."

Yue Zhang, Weiling Bai, Ruyue Li, Yifan Du, Runzhou Sun, Tao Li, Hong Kang, Ziwei Yang, Jianjun Tang, Ningli Wang, Hanruo Liu.
Cost-Utility Analysis of Screening for Diabetic Retinopathy in China.
Health Data Science, Volume 2022, Article ID 9832185, 2022. doi: 10.34133/2022/9832185

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...